Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00782561 · ClinicalTrials.gov registry record · Phase 1
Safety and Pharmacokinetics of FG-3019 in Adolescents and Adults With Focal Segmental Glomerulosclerosis (FSGS)
A Phase 1 study, sponsored by Kyntra Bio.
- Terminated
- Registry status
- Phase 1
- Development phase
- 2
- Enrollment target
NCT00782561 is a Phase 1 study that was terminated before completion, run by Kyntra Bio. The registered enrollment target is 2 participants.
The verdict
NCT00782561, a Phase 1 study, was terminated before completion, sponsored by Kyntra Bio.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 2 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the safety and tolerability of FG-3019 administered over 8 weeks to adolescent and adult subjects with steroid-resistant focal segmental glomerulosclerosis (FSGS).
Interventions
- DRUG FG-3019
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2 participants |
| Start Date | 2008-04 |
| Est. Completion | 2009-06-18 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00782561
The ClinicalTrials.gov registry entry for NCT00782561 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 2 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Kyntra Bio, which has 30 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which FG-3019 is the first listed.
NCT00782561 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00782561 about?
NCT00782561 is a clinical study titled "Safety and Pharmacokinetics of FG-3019 in Adolescents and Adults With Focal Segmental Glomerulosclerosis (FSGS)". The purpose of this study is to evaluate the safety and tolerability of FG-3019 administered over 8 weeks to adolescent and adult subjects with steroid-resistant focal segmental glomerulosclerosis (FSGS).
What is the current status of trial NCT00782561?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 2 participants. The study started on 2008-04. Estimated completion is 2009-06-18.
What interventions are being tested in trial NCT00782561?
The interventions under investigation include: FG-3019 (DRUG).
Who is sponsoring clinical trial NCT00782561?
This trial is sponsored by Kyntra Bio, which has 30 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.